There are over 1 million hospitalizations for heart failure per year in North America, most of which are driven by fluid overload. The gold standard therapy for patients admitted with congestive heart failure is IV diuretics. However, the process of treating patients with IV diuretics is challenging, with 1 in 4 patients having their diuretics stopped prematurely and 1 in 3 patients being discharged with residual congestion – factors that lead to increased lengths of hospital stays, and higher readmission rates. Much of this challenge is due to the lack of adequate hemodynamic monitoring of congestion in patients admitted to hospital with heart failure, particularly on general medical or cardiology wards where invasive hemodynamic monitoring is not permitted.
Venamic is an early-stage medical device company developing a novel non-invasive hemodynamic monitoring system for patients admitted to hospital with acute heart failure, particularly in non-critical care settings.
Founder & CEO
Our website uses cookies to ensure you get the best experience. Learn more about the policy.
Since 2011, we’ve helped over 160 startups launch and scale their businesses. This fall, network with 350+ entrepreneurs, investors, and leaders at a milestone evening where community, growth & collaboration meet innovation.
Meet the top 10 finalists, and watch as they pitch their innovations live to a panel of investors and experts for cash prizes!
When: September 25, 2025 | 5:00pm – 9:00pm
Where: Oakville Banquet & Conference Centre |
2515 Wyecroft Rd, Oakville, ON L6L 6P8